Astaka Holdings Limited: Responses to SIAS Queries on FY2025 Annual Report

Overview

Astaka Holdings Limited has released detailed responses to queries from the Securities Investors Association (Singapore) regarding its annual report for the financial year ended 31 December 2025. The responses cover critical developments in its property pipeline, strategic shifts into new business segments, and capital management, offering investors a comprehensive view of the Group’s outlook and risks.

Key Developments in Property Projects

One Bukit Senyum (OBS3) – Launch and Progress

• Arden @ One Bukit Senyum: Launched in March 2025, Arden achieved a strong take-up rate of 70% by year-end. Construction began in May and is targeted for completion by 2030. Arden features 618 premium serviced residences with an estimated gross development value (GDV) of RM800 million.
• Other OBS3 Components: The final phase includes a lifestyle retail mall (300,000 sq ft net lettable area), a 250-room hotel, and ~300 branded residences, with an estimated GDV of RM1.2 billion. Construction for these is expected to start in 2026 and finish by 2030.
• Financial Position: For Arden and Aliva @ Mount Austin, full project financing facilities have been secured, supported by bank loans, shareholder loans, and progressive sales proceeds. However, funding for the lifestyle retail mall is not yet secured and will be arranged as the project advances.

Bukit Pelali @ Pengerang – Strategic Review

• Despite completion of Phases 1A, 1B, 2A, and 2B, the Group has not finalized further development plans due to challenging market conditions and demand tied to ongoing industrial investments in the area, notably Petronas’ RM7.5 billion investment.
• Management is actively working with architects to refine master plans and optimize phasing, but the project’s future remains uncertain. Options such as divestment are under consideration, and any material developments will be announced in a timely manner.

Financial Performance

• FY2025 Revenue: RM94.6 million, primarily from Aliva @ Mount Austin. Arden is still in early construction; thus, revenue recognition is limited.
• Loss: The Group reported a loss attributable to owners of RM6.7 million, reflecting ongoing development and early-stage investments.

Entry into Consumer Healthtech Segment

• In February 2026, Astaka announced an exclusive distribution agreement with Evergrown Group, a manufacturer of sterilisation LED electrical equipment, marking its entry into the consumer healthtech segment.
• Due Diligence: The Board conducted commercial and technical assessments, including market analysis, technology review, and regulatory standing. The arrangement is structured as a distribution partnership with minimal upfront capital commitment, mitigating execution risks.
• Capital Investment: No material capital outlay or equity participation is involved at this stage; the Group will procure products for exclusive distribution, initially targeting Singapore.
• Interested Person Transaction: The arrangement does not constitute an interested person transaction under SGX rules, as the controlling shareholder’s indirect interest in Evergrown Group is below 5%.

Dividend Policy and Capital Management

• No Dividend Declared: The Group has not paid dividends for FY2025, prioritizing cash conservation for working capital and project pipelines. The last dividend was paid nearly a decade ago.
• Board’s Capital Structure Definition: The optimal capital structure balances debt and equity, maintaining prudent leverage, liquidity, and flexibility to fund operations and growth.
• Dividend Resumption Conditions: The Board will consider resuming dividends only if the Group achieves sustained profitability, stable cash flows, and sufficient financial headroom for both current and future development commitments.

Shareholder Considerations – Potential Price Sensitive Issues

• Strong Take-Up Rate: The 70% sales rate for Arden @ One Bukit Senyum may reflect positive demand and support for future revenue growth.
• Funding Uncertainty: The lack of secured funding for the lifestyle retail mall and the uncertain future of Bukit Pelali @ Pengerang could impact project timelines and financial performance.
• Strategic Diversification: Entry into the healthtech segment is a new growth driver, but carries execution risk and is not yet a material contributor to earnings.
• Dividend Outlook: Continued cash conservation signals that shareholders should not expect dividends in the near term, pending improvements in profitability and liquidity.

Conclusion

Astaka Holdings Limited is progressing with its flagship projects and cautiously diversifying into new business areas. However, uncertainties remain regarding the funding of certain developments, the future of Bukit Pelali, and the timing of dividend resumption. These factors, along with the Group’s financial performance and capital management decisions, are likely to influence investor sentiment and potentially affect share value in the near to medium term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell shares of Astaka Holdings Limited. Investors should conduct their own due diligence and consult with their financial advisers before making any investment decisions. The information is based on company disclosures as of 22 April 2026 and may be subject to change.

View Astaka Historical chart here